NASDAQ:DVAX Dynavax Technologies (DVAX) Stock Price, News & Analysis $11.06 -0.13 (-1.16%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$11.44 +0.39 (+3.48%) As of 08/7/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Dynavax Technologies Stock (NASDAQ:DVAX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Dynavax Technologies alerts:Sign Up Key Stats Today's Range$10.94▼$11.3050-Day Range$9.77▼$11.3652-Week Range$9.22▼$14.63Volume1.62 million shsAverage Volume1.23 million shsMarket Capitalization$1.33 billionP/E RatioN/ADividend YieldN/APrice Target$24.00Consensus RatingModerate Buy Company Overview Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California. Read More Dynavax Technologies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks86th Percentile Overall ScoreDVAX MarketRank™: Dynavax Technologies scored higher than 86% of companies evaluated by MarketBeat, and ranked 146th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingDynavax Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageDynavax Technologies has received no research coverage in the past 90 days.Read more about Dynavax Technologies' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth53.13% Earnings GrowthEarnings for Dynavax Technologies are expected to grow by 53.13% in the coming year, from $0.32 to $0.49 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dynavax Technologies is -21.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dynavax Technologies is -21.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDynavax Technologies has a P/B Ratio of 2.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Dynavax Technologies' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.25% of the float of Dynavax Technologies has been sold short.Short Interest Ratio / Days to CoverDynavax Technologies has a short interest ratio ("days to cover") of 7.8.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDynavax Technologies does not currently pay a dividend.Dividend GrowthDynavax Technologies does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-1.59 Percentage of Shares Shorted13.25% of the float of Dynavax Technologies has been sold short.Short Interest Ratio / Days to CoverDynavax Technologies has a short interest ratio ("days to cover") of 7.8.Change versus previous month News and Social Media3.3 / 5News Sentiment0.97 News SentimentDynavax Technologies has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Dynavax Technologies this week, compared to 5 articles on an average week.MarketBeat Follows2 people have added Dynavax Technologies to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Dynavax Technologies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.98% of the stock of Dynavax Technologies is held by insiders.Percentage Held by Institutions96.96% of the stock of Dynavax Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Dynavax Technologies' insider trading history. Receive DVAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dynavax Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address DVAX Stock News HeadlinesDecoding Dynavax Technologies Corp (DVAX): A Strategic SWOT Insight2 hours ago | gurufocus.comDynavax Technologies Corporation (DVAX) Q2 2025 Earnings Call Transcript4 hours ago | seekingalpha.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes. | Porter & Company (Ad)Dynavax (DVAX) Q2 Revenue Jumps 29%August 7 at 6:06 PM | fool.comDynavax Reports Second Quarter 2025 Financial ResultsAugust 7 at 4:00 PM | prnewswire.comDynavax Technologies (DVAX) to Release Earnings on ThursdayAugust 6 at 2:25 AM | americanbankingnews.comDynavax to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025July 29, 2025 | prnewswire.comDynavax Technologies Corporation (DVAX) - Yahoo FinanceJuly 12, 2025 | finance.yahoo.comSee More Headlines DVAX Stock Analysis - Frequently Asked Questions How have DVAX shares performed this year? Dynavax Technologies' stock was trading at $12.77 at the start of the year. Since then, DVAX stock has decreased by 13.4% and is now trading at $11.06. How were Dynavax Technologies' earnings last quarter? Dynavax Technologies Corporation (NASDAQ:DVAX) issued its quarterly earnings data on Thursday, August, 7th. The biopharmaceutical company reported $0.14 earnings per share for the quarter, topping analysts' consensus estimates of $0.12 by $0.02. Dynavax Technologies had a negative net margin of 20.39% and a positive trailing twelve-month return on equity of 3.59%. Read the conference call transcript. Who are Dynavax Technologies' major shareholders? Top institutional investors of Dynavax Technologies include Chicago Capital LLC (4.35%), Blair William & Co. IL (1.90%), Nordea Investment Management AB (0.65%) and Bank of New York Mellon Corp (0.58%). Insiders that own company stock include Andrew A F Hack, Ryan Spencer, Robert Janssen, Francis Cano, David F Novack and Justin Burgess. View institutional ownership trends. How do I buy shares of Dynavax Technologies? Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dynavax Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dynavax Technologies investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings8/07/2025Today8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:DVAX CIK1029142 Webwww.dynavax.com Phone(510) 848-5100Fax510-848-1327Employees350Year Founded1996Price Target and Rating Average Price Target for Dynavax Technologies$24.00 High Price Target$31.00 Low Price Target$10.00 Potential Upside/Downside+117.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.52) Trailing P/E RatioN/A Forward P/E Ratio34.56 P/E GrowthN/ANet Income$27.31 million Net Margins-20.39% Pretax Margin-18.85% Return on Equity3.59% Return on Assets2.20% Debt Debt-to-Equity Ratio0.49 Current Ratio11.93 Quick Ratio10.84 Sales & Book Value Annual Sales$277.25 million Price / Sales4.79 Cash Flow$0.16 per share Price / Cash Flow70.67 Book Value$4.54 per share Price / Book2.44Miscellaneous Outstanding Shares120,080,000Free Float116,503,000Market Cap$1.33 billion OptionableOptionable Beta1.09 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:DVAX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dynavax Technologies Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Dynavax Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.